227 related articles for article (PubMed ID: 8898703)
1. Kinetic evaluation of [11C]dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter.
Koeppe RA; Frey KA; Vander Borght TM; Karlamangla A; Jewett DM; Lee LC; Kilbourn MR; Kuhl DE
J Cereb Blood Flow Metab; 1996 Nov; 16(6):1288-99. PubMed ID: 8898703
[TBL] [Abstract][Full Text] [Related]
2. Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-alpha-[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography.
Koeppe RA; Frey KA; Kume A; Albin R; Kilbourn MR; Kuhl DE
J Cereb Blood Flow Metab; 1997 Sep; 17(9):919-31. PubMed ID: 9307605
[TBL] [Abstract][Full Text] [Related]
3. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine.
Koeppe RA; Frey KA; Kuhl DE; Kilbourn MR
J Cereb Blood Flow Metab; 1999 Dec; 19(12):1376-84. PubMed ID: 10598942
[TBL] [Abstract][Full Text] [Related]
4. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
Kilbourn MR; Kuszpit K; Sherman P
Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
[TBL] [Abstract][Full Text] [Related]
5. In vivo measures of dopaminergic radioligands in the rat brain: equilibrium infusion studies.
Kilbourn MR; Sherman PS; Kuszpit K
Synapse; 2002 Mar; 43(3):188-94. PubMed ID: 11793424
[TBL] [Abstract][Full Text] [Related]
6. Analysis of four dopaminergic tracers kinetics using two different tissue input function methods.
Sossi V; Holden JE; Chan G; Krzywinski M; Stoessl AJ; Ruth TJ
J Cereb Blood Flow Metab; 2000 Apr; 20(4):653-60. PubMed ID: 10779009
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo studies of benzisoquinoline ligands for the brain synaptic vesicle monoamine transporter.
Lee LC; Vander Borght T; Sherman PS; Frey KA; Kilbourn MR
J Med Chem; 1996 Jan; 39(1):191-6. PubMed ID: 8568807
[TBL] [Abstract][Full Text] [Related]
8. In vivo measurement of the vesicular monoamine transporter in schizophrenia.
Taylor SF; Koeppe RA; Tandon R; Zubieta JK; Frey KA
Neuropsychopharmacology; 2000 Dec; 23(6):667-75. PubMed ID: 11063922
[TBL] [Abstract][Full Text] [Related]
9. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF
Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687
[TBL] [Abstract][Full Text] [Related]
10. Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C]dihydrotetrabenazine and positron emission tomography.
Gilman S; Koeppe RA; Adams KM; Junck L; Kluin KJ; Johnson-Greene D; Martorello S; Heumann M; Bandekar R
Ann Neurol; 1998 Sep; 44(3):326-33. PubMed ID: 9749598
[TBL] [Abstract][Full Text] [Related]
11. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.
Frey KA; Koeppe RA; Kilbourn MR; Vander Borght TM; Albin RL; Gilman S; Kuhl DE
Ann Neurol; 1996 Dec; 40(6):873-84. PubMed ID: 9007092
[TBL] [Abstract][Full Text] [Related]
12. Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects.
Chan GL; Holden JE; Stoessl AJ; Samii A; Doudet DJ; Dobko T; Morrison KS; Adam M; Schulzer M; Calne DB; Ruth TJ
J Nucl Med; 1999 Feb; 40(2):283-9. PubMed ID: 10025836
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of scopolamine on in vivo binding of dopamine transporter and vesicular monoamine transporter radioligands in rat brain.
Kilbourn MR; Kemmerer ES; Desmond TJ; Sherman PS; Frey KA
Exp Neurol; 2004 Aug; 188(2):387-90. PubMed ID: 15246838
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of serotonergic transporters using PET and [11C](+)McN-5652: assessment of methods.
Buck A; Gucker PM; Schönbächler RD; Arigoni M; Kneifel S; Vollenweider FX; Ametamey SM; Burger C
J Cereb Blood Flow Metab; 2000 Feb; 20(2):253-62. PubMed ID: 10698061
[TBL] [Abstract][Full Text] [Related]
15. Decreased platelet vesicular monoamine transporter density in habitual smokers.
Schwartz K; Weizman A; Rehavi M
Eur Neuropsychopharmacol; 2005 Mar; 15(2):235-8. PubMed ID: 15695071
[TBL] [Abstract][Full Text] [Related]
16. In vivo imaging of the brain vesicular monoamine transporter.
Vander Borght TM; Kilbourn MR; Koeppe RA; DaSilva JN; Carey JE; Kuhl DE; Frey KA
J Nucl Med; 1995 Dec; 36(12):2252-60. PubMed ID: 8523116
[TBL] [Abstract][Full Text] [Related]
17. Quantification of muscarinic cholinergic receptors with [11C]NMPB and positron emission tomography: method development and differentiation of tracer delivery from receptor binding.
Zubieta JK; Koeppe RA; Mulholland GK; Kuhl DE; Frey KA
J Cereb Blood Flow Metab; 1998 Jun; 18(6):619-31. PubMed ID: 9626186
[TBL] [Abstract][Full Text] [Related]
18. Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration.
Tong J; Wilson AA; Boileau I; Houle S; Kish SJ
Synapse; 2008 Nov; 62(11):873-6. PubMed ID: 18720517
[TBL] [Abstract][Full Text] [Related]
19. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium.
Staal RG; Hogan KA; Liang CL; German DC; Sonsalla PK
J Pharmacol Exp Ther; 2000 May; 293(2):329-35. PubMed ID: 10772999
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of a [11C]methoxy derivative of alpha-dihydrotetrabenazine: a radioligand for studying the vesicular monoamine transporter.
DaSilva JN; Kilbourn MR; Mangner TJ
Appl Radiat Isot; 1993 Dec; 44(12):1487-9. PubMed ID: 7903060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
